IntegraGen announced today the presentation scientific data which demonstrates the role of common genetic variants towards the identificaiton of risk of autism in siblings of children diagnosed with autism spectrum disorders during the 2012 International Meeting for Autism Research. 

Link to press release

IntegraGen announced today financial results for the year ending December 31, 2011. 

Annual Results 2011

IntegraGen, Inc. Names Michael Dresner National Sales Director

Cambridge, MA (April 17, 2012) - IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, has named Michael E. Dresner National Sales Director. He will be responsible for IntegraGen's sales efforts in the U.S. associated with the ARISk™ Autism Risk Assessment Test. 

Link to press release 

Apr. 4th, 2012 - IntegraGen Launches ARISk™ Test, a Genetic Screening Tool for Autism in High-Risk Children        

The ARISk™ Test Screens Children in Multiplex Families As Early As Six Months by Looking at 65 Genetic Markers Associated With Autism, Paving Way for Early Intervention and Best Outcomes

Read the PRESS RELEASE

EVRY, THURSDAY 8TH DECEMBER 2011 - IntegraGen, has announced the appointment of Laurence Riot Lamotte as Chief Financial Officer.

Bernard Courtieu, Chief Executive Officer, comments: “We are delighted to welcome Laurence Riot Lamotte to our teams. Laurence has substantial international experience, considerable knowledge of the health sector and developed, in her previous jobs, solid expertise in mergers and acquisitions, raising capital and investor relations. Furthermore, she is driven by a strong entrepreneurial spirit. All these qualities will be valuable assets to accompany IntegraGen through its ambitious growth plan, in Europe and the United States.”

IntegraGen has been certified by Agilent for all SureSelect target enrichment protocols, for use with Illumina sequencing HiSeq2000 platform.

Apr. 27th. : IntegraGen announced that OSEO (the French state innovation agency) had awarded a total of €1.6 million in financial support to a collaborative project with the French National Institute of Health and Medical Research (INSERM).

Download Press Release

Oncology - liver and colon cancer : award of OSEO funding for a biomarker panel development project

Evry (France), April 27, 2011.  IntegraGen announced that OSEO (the French state innovation agency) had awarded a total of €1.6 million in financial support to a collaborative project with the French National Institute of Health and Medical Research (INSERM). The financial support covers a 3-year period and will be supplied by OSEO as an interest-free loan that will be repayable from 2015 onwards if the project is successful.

The project (to be performed in collaboration with INSERM units U674 and U775) is notably based on promising research themes identified during the Carte d'Identité des Tumeurs ("Tumor ID Card") program funded by the French National League Against Cancer. The collaboration aims at developing
The project (to be performed in collaboration with INSERM units U674 and U775) is notably based on promising research themes identified during the Carte d'Identité des Tumeurs ("Tumor ID Card") program funded by the French National League Against Cancer. The collaboration aims at developing.

IntegraGen announced today that it has entered into an exclusive licensing agreement with The Johns Hopkins University and Massachusetts General Hospital to commercialize genetic tests that identify children at risk for autism which include a mutation to the Jumonji, AT Rich Interactive Domain 2 (JARID2) gene.

Dowload press release (PDF)

IntegraGen announces exclusive licensing agreement with the John Hopkins University and Massachusetts General Hospital for autism gene.

EVRY (FRANCE) - APRIL 11, 2011 - IntegraGen, a French biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today that it has entered into an exclusive licensing agreement with The Johns Hopkins University and Massachusetts General Hospital to commercialize genetic tests that identify children at risk for autism which include a mutation to the Jumonji, AT Rich Interactive Domain 2 (JARID2) gene.